Details of the Drug

General Information of Drug (ID: DMCIY7N)

Drug Name
CRL-8131
Synonyms Flocor; RheothRx; Poloxamer 331; ANX-188; CRL-5861; P-188; Poloxamer-188; RheothRx-pf
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Phase 3 [1]
Non-small-cell lung cancer 2C25.Y Phase 3 [2]
Sickle-cell disorder 3A51 Phase 3 [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C5H10O2
Canonical SMILES
CC1CO1.C1CO1
InChI
InChI=1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2
InChIKey
RVGRUAULSDPKGF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
24751
ChEBI ID
CHEMBL32026
CAS Number
691397-13-4
UNII
V8B3K56SW0
DrugBank ID
DB11451
TTD ID
D0W0SM
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT00004408) Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01737814) Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)